Visceral adipose tissue and risk of COVID-19 susceptibility, hospitalization, and severity: A Mendelian randomization study

Lu Chen¹, Xingang Sun¹, Deheng Han, Jiawei Zhong, Han Zhang and Liangrong Zheng*

Department of Cardiology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Background: Coronavirus Disease 2019 (COVID-19) has rapidly evolved as a global pandemic. Observational studies found that visceral adipose tissue (VAT) increased the likelihood of worse clinical outcomes in COVID-19 patients. Whereas, whether VAT is causally associated with the susceptibility, hospitalization, or severity of COVID-19 remains unconfirmed. We aimed to investigate the causal associations between VAT and susceptibility, hospitalization, and severity of COVID-19.

Methods: We applied a two-sample Mendelian randomization (MR) study to infer causal associations between VAT and COVID-19 outcomes. Single-nucleotide polymorphisms significantly associated with VAT were derived from a large-scale genome-wide association study. The random-effects inverse-variance weighted method was used as the main MR approach, complemented by three other MR methods. Additional sensitivity analyses were also performed.

Results: Genetically predicted higher VAT mass was causally associated with higher risks of COVID-19 susceptibility (ORs = 1.13; 95% confidence interval (CI), 1.09–1.17; \(P = 4.37 \times 10^{-12}\)), hospitalization (OR = 1.51; 95% CI = 1.38–1.65; \(P = 4.14 \times 10^{-20}\)), and severity (OR = 1.58; 95% CI = 1.38–1.82; \(P = 7.34 \times 10^{-11}\)).

Conclusion: This study provided genetic evidence that higher VAT mass was causally associated with higher risks of susceptibility, hospitalization, and severity of COVID-19. VAT can be a useful tool for risk assessment in the general population and COVID-19 patients, as well as an important prevention target.

Keywords: COVID-19, visceral adipose tissue, Mendelian randomization, causal associations, risk

Introduction

Coronavirus Disease 2019 (COVID-19), an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly evolved as a global pandemic (1). By 28 September 2022, a total of 613,410,796 people have been diagnosed with COVID-19 and 6,518,749 people confirmed deaths globally (1).
Thus, it is important to recognize risk factors for this disease and determine prevention strategies.

Emerging literature has suggested that obesity is correlated with the risk, severity, and prognosis of COVID-19 (2–5). In these studies, obesity was commonly assessed by body mass index (BMI), estimated by the ratio of weight over height. However, since obesity is a heterogeneous disorder, there are considerable individual variations in the body fat distribution and metabolic profile even with the same BMI (6). Visceral adipose tissue (VAT) is the adiposity accumulated around abdominal viscera, which can be measured by several imaging technologies, including magnetic resonance imaging, computed tomography (CT), and dual-energy X-ray absorptiometry (DXA) (7). VAT is considered as a marker of ectopic fat deposition and disturbed hormonal milieu, and is metabolically more active compared with subcutaneous adipose tissue (8). Recently, several observational studies found that VAT increased the likelihood of worse clinical outcomes in COVID-19 patients (9–11). Whereas, the current data seldom investigated the relationship between VAT and susceptibility and hospitalization of COVID-19. In addition, the causal associations between VAT and COVID-19 outcomes remain unconfirmed.

Mendelian randomization (MR) is a widely used epidemiology method with genetic variants utilized as instrumental variables (IVs) to perform causal inferences between exposures (risk factors) and outcomes (diseases) (12). Since observational studies are prone to the possibility of unmeasured confounders and reverse causation, the observed exposure-outcome association may not reflect an accurate causal relationship (13). Besides, although randomized controlled trials (RCTs) can demonstrate causality with high evidence level, well-designed RCTs are often expensive and time-consuming, and not always ethical (14). As genetic variants are randomly and independently inherited at conception and prior to the development of diseases, MR study provides a natural experiment simulating an RCT but avoids confounding from environmental effects and reverse causality. In this study, we aimed to apply two-sample MR analyses to infer the causal effects of VAT on susceptibility, hospitalization, and severity of COVID-19.

Methods

Study design

The present study used summary data from a large-scale genome-wide association study (GWAS) for VAT and the COVID19 Host Genetics Initiative for COVID-19 outcomes. The study was based on 3 important assumptions: (1) genetic variants selected as IVs should be significantly associated with the exposure (VAT), (2) IVs should not be associated with any confounders, and (3) IVs should not affect the outcome (COVID-19 outcomes) through any other pathways except the exposure (VAT). We first applied a two-sample MR study to infer causal associations between VAT and COVID-19 outcomes. Then, we conducted multivariable MR (MVMR) analyses to investigate the direct effect of VAT on COVID-19 outcomes. Supplementary analyses were also performed to minimize the bias caused by population stratification and sample overlap. The overview of the study design was displayed in Figure 1.

VAT data sources

Summary data for VAT were derived from a recent large-scale GWAS performed by Karlsson et al. (15). This study used two sub-cohorts to predict VAT in UK Biobank, with VAT-training dataset measured by DXA used to create prediction models and VAT-application dataset used to calculate VAT according to the prediction models. Overall, the training dataset involved 4,198 participants and the application dataset involved 325,153 participants. We selected single-nucleotide polymorphisms (SNPs) significantly associated with VAT mass at the genome-wide significance level ($P < 5 \times 10^{-8}$) and further pruned those SNPs for independence ($r^2 = 0.001; >10,000\text{ kb}$) by “clump_data” function in “TwoSampleMR” package. Finally, we obtained 221 VAT-associated SNPs which were used as IVs in further analyses (Supplementary Table 1).

Outcome data sources

As shown in Table 1, the summary-level data for COVID-19 outcomes (including susceptibility, hospitalization, and severity of COVID-19) were obtained from the COVID19 Host Genetics Initiative (round 6, released on June 15, 2021, https://www.covid19hg.org/results/r6/), an ongoing initiative which aims to facilitate COVID-19 genetic host research through bringing together the human genetics data. To study the risk of COVID-19 susceptibility, we downloaded the GWAS meta-analysis of “Covid vs. population” (C2_ALL_leave_23andme), in which cases were defined as individuals who reported SARS-CoV-2 infection regardless of symptoms and controls were defined as non-cases (16). This GWAS meta-analysis involved 112,612 cases and 2,474,079 controls. For COVID-19 hospitalization, we downloaded the GWAS meta-analysis of “Hospitalized covid vs. population” (B2_ALL_leave_23andme), with cases defined as SARS-CoV-2 infected individuals who were hospitalized due to COVID-19-related symptoms and controls defined as non-cases (16). There were 24,274 cases and 2,061,529 controls in this GWAS. Additionally, we downloaded the GWAS...
FIGURE 1
Overview of the study design. The study was based on 3 important assumptions: 1, genetic variants selected as instrumental variables (IVs) should be significantly associated with the exposure (VAT), 2, IVs should not be associated with any confounders, and 3, IVs should not affect the outcome (COVID-19 outcomes) through any other pathways except the exposure (VAT). VAT, visceral adipose tissue; MR, Mendelian randomization; COVID-19, Coronavirus Disease 2019.

TABLE 1  Characteristics of the data sources for COVID-19 outcomes.

| Phenotype | Traits | Ancestry | Cases   | Controls  | UKB | Sample overlap* | Use | Release (URL) |
|-----------|--------|----------|---------|-----------|-----|----------------|-----|---------------|
| C2: Reported SARS-CoV-2 infection vs. population controls | COVID-19 susceptibility | Mixed   | 112,612  | 2,474,079 | 441,331 | ≤ 12.6% | Primary analyses | r6 (https://www.covid19hg.org/results/r6/) |
| B2: Hospitalized COVID19+ vs. population controls | COVID-19 hospitalization | Mixed   | 24,274   | 2,061,529 | 436,043 | ≤ 15.6% | Primary analyses | r6 (https://www.covid19hg.org/results/r6/) |
| A2: Critically ill COVID19+ vs. population controls | COVID-19 severity | Mixed   | 8,779    | 1,001,875 | 420,531 | ≤ 32.2% | Primary analyses | r6 (https://www.covid19hg.org/results/r6/) |
| C2: Reported SARS-CoV-2 infection vs. population controls (European, leave UKB) | COVID-19 susceptibility | European | 74,614   | 1,803,529 | 0  | 0 | Supplementary analyses | r6 (https://www.covid19hg.org/results/r6/) |
| B2: Hospitalized COVID19+ vs. population controls (European, leave UKB) | COVID-19 hospitalization | European | 14,925   | 1,393,029 | 0  | 0 | Supplementary analyses | r6 (https://www.covid19hg.org/results/r6/) |
| A2: Critically ill COVID19+ vs. population controls (European, leave UKB) | COVID-19 severity | European | 4,297    | 374,224  | 0  | 0 | Supplementary analyses | r5 (https://www.covid19hg.org/results/r5/) |

COVID-19, Coronavirus Disease 2019; UKB, UK Biobank. *The overlapping sample size (assuming that all of the overlapping samples appeared in the cohorts of exposure and outcome) was divided by the larger sample size of the corresponding outcome trait and exposure.

meta-analysis of “Very severe respiratory confirmed covid vs. population” (A2_ALL_leave_23andme) for COVID-19 severity. This GWAS meta-analysis consisted of 8,779 cases and 1,001,875 controls, with cases defined as SARS-CoV-2 infected individuals who required respiratory support or had died and controls defined as non-cases (16). If the SNPs were unavailable in the outcome datasets, we searched for proxy SNPs in high linkage disequilibrium ($r^2 > 0.8$) by using an online website (http://snipa.helmholtz-muenchen.de/snipa3/) (Supplementary Table 2).
Statistical analysis

In the primary MR analyses, we applied the random-effects inverse-variance-weighted (IVW) method as the main MR approach to obtain causal estimates between VAT and COVID-19 outcomes. We also performed other three MR methods to test the stability of the IVW results, including weighted median, MR-Egger, and MR-pleiotropy residual sum and outlier (MR-PRESSO). The weighted median method generates robust and consistent causal estimates, assuming that more than 50% of the weights are derived from valid SNPs. The MR-Egger was performed to evaluate horizontal pleiotropy with P-value for its intercept and provide pleiotropy-corrected estimates if significant horizontal pleiotropy was detected by the intercept test; however, this model usually consumes statistical power. The MR-PRESSO method can identify outliers and generate causal estimates after removing the outliers. For sensitivity analyses, we used the Cochran’s Q-statistic and I² and P-value for the intercept in MR-Egger to detect heterogeneity (PQ-statistics < 0.05 or I² > 25%) and horizontal pleiotropy (Pintercept < 0.05). We also performed the leave-one-out analysis to investigate whether the association was driven by any single SNP. Regression-based MVMR analyses were further conducted to investigate the direct effect of VAT on COVID-19 outcomes, independent from the effect of BMI which was highly correlated with VAT. Genetic associations of instruments with BMI were obtained from publicly available GWAS (17). We used the mRnd (http://cnsgenomics.com/shiny/mRnd/), a web application, to estimate the required OR of the exposure on the outcome to achieve 80% statistical power.

As there was some sample overlap (UK Biobank) between the GWAS of VAT and COVID-19 outcomes and the ancestries of participants in COVID-19 outcomes were mixed (Table 1), we further performed supplementary analyses by utilizing European-ancestry specific summary statistics which also leaves UK Biobank cohort out to minimize the bias caused by population stratification and sample overlap. Detailed information was presented in Table 1.

Results were reported as odds ratios (ORs) and corresponding 95% confidence intervals (CIs) of COVID-19 outcomes which were scaled to one standard deviation (SD) increase in genetically predicted VAT mass. Accounting for three outcomes included in the study, we set P-values < 0.017 (0.05/3) as statistical significance. Associations with P-values between 0.05 and 0.017 were regarded as suggestive associations. No ethical approval was required as this study used summary-level data from the published studies and publicly available GWASs. We performed MR analyses in R version 4.0.2 using the R packages TwoSampleMR (18), MR-PRESSO (19), and MendelianRandomization (20).

Results

A total of 221 SNPs were identified as IVs for predicted VAT mass. These SNPs explained ~3.70% variance in VAT mass. The F-statistics for each SNP ranged from 29.72 to 658.12, reflecting a low possibility of weak instruments. There was >80% statistical power to detect significant differences at an OR of 1.05 or higher for COVID-19 susceptibility, 1.10 or higher for COVID-19 hospitalization, and 1.16 or higher for COVID-19 severity (Supplementary Table 3).

In the standard IVW analyses, as shown in Figure 2, we observed strong evidence of causal associations of the increased VAT mass with higher risks of COVID-19 susceptibility (OR = 1.13; 95% CI, 1.09–1.17; P = 4.37 × 10⁻¹²), COVID-19 hospitalization (OR = 1.51; 95% CI, 1.38–1.65; P = 4.14 × 10⁻²⁰), and COVID-19 severity (OR = 1.58; 95% CI = 1.38–1.82; P = 7.34 × 10⁻¹¹). Results from the weighted median and MR-Egger methods were robust and consistent, except for COVID-19 susceptibility and severity in MR-Egger, which showed a similar pattern of effect but with broader CIs (Figure 2). The intercept term in MR-Egger regression suggested no significant overall horizontal pleiotropy (all Pintercept > 0.05; Table 2). However, there was some evidence of heterogeneity for COVID-19 susceptibility and hospitalization measured by Cochran Q and I² (PQ-statistics = 1.61 × 10⁻⁴, I² = 27.5% for COVID-19 susceptibility, and PQ-statistics = 0.006, I² = 20.4% for COVID-19 hospitalization, respectively; Table 2). MR-PRESSO outlier test detected one outlier (rs13135092) in the analyses for COVID-19 susceptibility and one outlier (rs1446585) in the analyses for COVID-19 hospitalization. Whereas, after excluding these outliers, the results still indicated that genetically predicted increased VAT was associated with higher risks of COVID-19 susceptibility and hospitalization. The leave-one-out analysis further illustrated that the MR estimates were not driven by any individual SNP.

According to the MVMR analyses adjusting for BMI, although the MR estimates were attenuated, there was still suggestive evidence of associations of VAT with COVID-19 susceptibility (OR = 1.09; 95% CI, 1.00–1.19; P = 0.041), hospitalization (OR = 1.25; 95% CI, 1.02–1.54; P = 0.031), and severity (OR = 1.46; 95% CI, 1.05–2.03; P = 0.023; Figure 3), indicating that the effect of VAT on COVID-19 outcomes were independent of the effect from BMI.

When performing the supplementary analyses by utilizing COVID-19 GWAS summary statistics constrained to European ancestry and excluding the UK Biobank cohort, the results were generally consistent and stable across all MR methods, although weakened associations were observed for COVID-19 severity in the weighted median method and for both COVID-19 hospitalization and severity in
FIGURE 2
Associations of genetically predicted VAT mass with COVID-19 outcomes in primary analyses. VAT, visceral adipose tissue; COVID-19, Coronavirus Disease 2019; SNPs, single nucleotide polymorphisms; OR, odds ratio; CI, confidence interval; IVW, inverse-variance weighted; MR-PRESSO, MR-pleiotropy residual sum and outlier.

TABLE 2 Heterogeneity and pleiotropy assessment in primary analyses.

| Outcomes             | SNPs | $P_{Q}$—statistics | $I^2$ (%) | $P_{\text{intercept}}$ | $P_{\text{MR-PRESSO global test}}$ | Outlier   |
|----------------------|------|--------------------|-----------|------------------------|-------------------------------------|-----------|
| COVID-19 susceptibility | 221  | $1.61 \times 10^{-4}$ | 27.5      | 0.535                  | $<$0.001                            | rs13135092 |
| COVID-19 hospitalization | 221  | 0.006              | 20.5      | 0.488                  | 0.008                               | rs1446585 |
| COVID-19 severity     | 219  | 0.428              | 1.4       | 0.923                  | 0.431                               | –         |

SNPs, single nucleotide polymorphisms; MR-PRESSO, Mendelian randomization pleiotropy residual sum and outlier; COVID-19, Coronavirus Disease 2019.

FIGURE 3
MVMR analyses of the associations of genetically predicted VAT mass with COVID-19 outcomes adjusting for BMI. MVMR, multivariable Mendelian randomization; VAT, visceral adipose tissue; COVID-19, Coronavirus Disease 2019; BMI, body mass index; OR, odds ratio; CI, confidence interval.
MR-Egger method (Supplementary Figure 1). We found no evidence of horizontal pleiotropy indicated by intercepts and modest heterogeneity in the analyses for COVID-19 susceptibility and hospitalization (Supplementary Table 4). The leave-one-out analysis confirmed that the results were stable when eliminating the SNPs one by one (Supplementary Table 5).

Discussion

In this two-sample MR study, we found that genetically predicted higher VAT was associated with increased risks of COVID-19 susceptibility, hospitalization, and severity. The associations remained in the MVMR analyses adjusting for BMI and supplementary analyses.

Recent studies have suggested that VAT was correlated with adverse outcomes in COVID-19 patients (9–11, 21, 22). The relationship between VAT and COVID-19 was firstly investigated by Petersen et al. (10) in a cross-sectional pilot study involving 30 patients with COVID-19. They found that VAT specifically increased the likelihood of severe courses of COVID-19. This finding was confirmed by later studies. Yang et al. (23) conducted a retrospective study of 143 COVID-19 patients to assess the association between abdominal adipose tissue distribution and the severity of COVID-19, which suggested that patients with higher VAT were more likely to develop critical illness. In another retrospective study with 51 COVID-19 infected patients undergoing abdominopelvic CT, Chandarana et al. (9) observed higher VAT in COVID-19 patients that required hospitalization compared with those outpatients. Furthermore, the addition of VAT to the clinical model significantly improved its performance for identifying patients requiring hospitalization (9). Similarly, Favre et al. (11) identified high visceral fat amount as a stronger predictor of COVID-19 severity in European adults compared with BMI.

However, most previous observational studies were retrospective and conducted in single-center, with relatively small sample sizes. The possibility of selection bias, unmeasured confounding, and reverse causation should also be considered. Thus, large-scale studies are warranted to confirm these results. Utilizing summary-level data from large-scale GWASs, this MR study confirmed that genetically predicted higher VAT was associated with elevated risks of susceptibility, hospitalization, and severity of COVID-19, largely consistent with the results of previous studies.

Several VAT-related biological mechanisms may explain the observed causal associations. It was reported that individuals with greater levels of VAT had higher levels of adiposity-related inflammation (24). The infiltration of macrophages among hypertrophied adipocytes leads to elevated secretion of inflammatory cytokines, including tumor necrosis factor α and interleukin 6, and decreased production of adiponectin, a protective adipokine (25). Among COVID-19+ VAT, Colleluori et al. (26) detected a higher prevalence of CD68+ macrophages, which supported the presence of higher local VAT inflammation. In addition, angiotensin-converting enzyme 2 receptor was found to be highly expressed in VAT and may play a role in increasing the viral entry of SARS-CoV-2 (27, 28). Furthermore, VAT was correlated with many health and metabolic abnormalities, such as brain health, type 2 diabetes, cardiovascular and respiratory diseases, and cancers (29), and previous studies have demonstrated associative evidence between many of these conditions and COVID-19 (30–32).

The current results have implications for clinical practice. Since genetically predicted higher VAT was correlated with increased risks of COVID-19 susceptibility, hospitalization, and severity, VAT might be a useful and important tool for risk assessment in the general population and COVID-19 patients. As many hospitalized COVID-19 patients undergo chest or abdominal CT scans for the purpose of diagnosis or clinical care, these CTs can be used to quantify VAT but with no additional costs or radiation exposure. Besides, the reduction of VAT through aerobic exercise and caloric restriction may play a role in reducing the risk of getting infected and developing severe courses of COVID-19 (33, 34), which warrants further investigation. Moreover, a recent prospective study found that a higher baseline BMI was correlated with a reduced adaptive response to the COVID-19 mRNA vaccine; however, weight loss seemed effective at reversing this negative effect in subjects with obesity (35). Further research is also needed to evaluate the impact of VAT reduction on COVID-19 susceptibility by affecting the immune response to the COVID-19 vaccine.

The major strength of this study is that we applied the MR method to infer the causal associations between VAT and the risks of COVID-19 susceptibility, hospitalization, and severity, utilizing summary-level data derived from large-scale GWASs, which avoids residual confounding and reverse causality. Besides, in order to minimize the bias caused by population stratification and sample overlap, we conducted supplementary analyses utilizing European-ancestry-specific summary statistics and excluding the UK Biobank cohort. However, our study still has several limitations. First, we did not perform age or sex-stratified analyses due to a lack of available summary-level data for COVID-19. Second, pleiotropy is a major issue for any MR study. Nonetheless, we detected no significant overall horizontal pleiotropy from the intercept term in MR-Egger regression. In addition, the causal associations remained consistent after excluding the outliers and adjusting for BMI in the MVMR analyses. Third, since MR studies are vulnerable to selection bias due to inevitably recruiting participants surviving the genetic instruments and competing for risk of COVID-19 (36), further investigations are needed to confirm the results of this study.
Conclusion

In conclusion, this MR study provided genetic evidence that higher VAT was associated with increased risks of COVID-19 susceptibility, hospitalization, and severity, highlighting that VAT can be a useful and important tool for risk assessment in the general population and COVID-19 patients and VAT management may play a pivotal role in reducing the risk of getting infected and developing severe courses of COVID-19.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

LC and LZ designed the study. LC, XS, DH, JZ, and HZ performed the data analysis and interpreted the data. All authors were involved in writing the paper and had final approval of the submitted and published versions.

Funding

This study was supported by the National Natural Science Foundation of China (No. 81873484).

Acknowledgments

We thank Karlsson et al. (15) and the COVID19 Host Genetics Initiative for conducting the GWASs and making the summary statistics publicly available.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2022.1023935/full#supplementary-material

References

1. World Health Organization. Coronavirus Disease (COVID-19). (2022) Available online at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (accessed September 28, 2022).

2. Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. (2020) 21:e13128. doi: 10.1111/obr.13128

3. Gao F, Zheng KL, Wang XB, Sun QF, Pan KH, Wang TY, et al. Obesity is a risk factor for greater COVID-19 severity. Diabetes Care. (2020) 43: e72–e4. doi: 10.2337/dc20-0682

4. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. (2020) 71:896–7. doi: 10.1093/cid/ciaa145

5. Rao X, Wu C, Wang S, Tong S, Wang G, Wu G, et al. The importance of overweight in COVID-19: a retrospective analysis in a single center of Wuhan, China. Medicine. (2020) 99:e22766. doi: 10.1097/MD.0000000000022766

6. Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. (2012) 126:1301–13. doi: 10.1161/CIRCULATIONAHA.111.126264

7. Ross R, Soni S, Houle SA. Negative energy balance induced by exercise or diet: effects on visceral adipose tissue and liver fat. Nutrients. (2020) 12:891. doi: 10.3390/nu12040891

8. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. (2010) 11:11–8. doi: 10.1111/j.1467-789X.2009.00623.x

9. Chandarana H, Daze B, Mikkhe A, Tafel MT, Feng Y, Rusinek H. Visceral adipose tissue in patients with COVID-19: risk stratification for severity. Abdom Radiol. (2021) 46:818–25. doi: 10.1007/s00261-020-02693-2

10. Petersen A, Bressem K, Albrecht J, Thieß HM, Vahldiek J, Hamm B, et al. The role of visceral adiposity in the severity of COVID-19: highlights from a monocenter cross-sectional pilot study in Germany. Metabolism. (2020) 110:154317. doi: 10.1016/j.metabol.2020.154317

11. Favre G, Legueult K, Pradier C, Raffaelli C, Ichai C, Iannelli A, et al. Visceral fat is associated to the severity of COVID-19. Metabolism. (2021) 115:154440. doi: 10.1016/j.metabol.2020.154440

12. Endin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA. (2017) 318:1925–6. doi: 10.1001/jama.2017.17219

13. Sekula P, Del Greco MF, Pattaro C, Kottgen A. Mendelian randomization as an approach to assess causality using observational data. J Am Soc Nephrol. (2016) 27:3253–65. doi: 10.1681/ASN.2016010098

14. Evans DM, Davey Smith G. Mendelian randomization: new applications in the coming age of hypothesis-free causality. Annu Rev Genomics Hum Genet. (2015) 16:327–50. doi: 10.1146/annurev-genom-090314-050016

15. Karlsson T, Rask-Andersen M, Pan G, Höglund J, Wadelius C, Ekbom A, et al. Contribution of genetics to visceral adiposity and its relation to cardiovascular and metabolic diseases. Nat Med. (2019) 25:1390–5. doi: 10.1038/s41591-019-0563-7

16. Ganna A. Mapping the human genetic architecture of COVID-19. Nature. (2021) 600:472–7. doi: 10.1038/s41586-021-03970-x
The MR-Base platform supports systematic causal inference across the human genome, permitting Mendelian randomization analyses using summarized data. This approach is particularly useful in Mendelian randomization studies, where horizontal pleiotropy in causal relationships inferred from Mendelian randomization analyses using summarized data. The platform facilitates the examination of complex traits and diseases, providing a robust framework for understanding genetic influences on health outcomes.

17. Hoffmann TJ, Choquet H, Yin J, Banda Y, Kräle MN, Glymour M, et al. A large multiethnic genome-wide association study of adult body mass index identifies novel loci. *Genetics.* (2018) 210:499–515. doi: 10.1534/genetics.118.301479

18. Hennami G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human genome. *Elife.* (2018) 7:e34408. doi: 10.7554/eLife.34408

19. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet.* (2018) 50:693–9. doi: 10.1038/s41588-018-0099-7

20. Yavorska OO, Burgessa S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. *Int J Epidemiol.* (2017) 46:1734–9. doi: 10.1093/ije/dyx034

21. Ogata H, Morit M, Jingushi Y, Matsuzaki H, Katahira K, Ishimatsu A, et al. Impact of visceral fat on the prognosis of coronavirus disease 2019: an observational cohort study. *BMC Infect Dis.* (2021) 21:1240. doi: 10.1186/s12879-021-06958-a

22. Goehler A, Hsu TH, Seiglie JA, Siedner MJ, Lo J, Truant V, et al. Visceral adiposity and severe COVID-19 disease: application of an artificial intelligence algorithm to improve clinical risk prediction. *Open Forum Infect Dis.* (2021) 8:ofab275. doi: 10.1093/ofid/ofab275

23. Yang Y, Ding L, Zou X, Shen Y, Hu D, Hu X, et al. Visceral adiposity and high intramuscular fat deposition independently predict critical illness in patients with SARS-CoV-2. *Obesity.* (2020) 28:2040–8. doi: 10.1002/oby.22971

24. Delker E, Alyami B, Gallo LC, Ruiz JM, Skidmo M, Allison MA. Chronic stress burden, visceral adipose tissue, and adiposity-related inflammation: the multi-ethnic study of atherosclerosis. *Psychosom Med.* (2021) 83:834–42. doi: 10.1097/PSY.0000000000000983

25. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. *Nat Rev Immunol.* (2011) 11:85–97. doi: 10.1038/nri2921

26. Colléluori G, Graciotti L, Pesaresi M, Di Vincenzo A, Perugini I, Di Mercurio E, et al. Visceral fat inflammation and fat embolism are associated with lung’s lipidic hyaline membranes in subjects with COVID-19. *Int J Obes.* (2022) 2022:1–9. doi: 10.1101/2021.10.30.466586

27. Zhang Y, Somers KR, Becari C, Polonos K, Pfeifer MA, Allen AM, et al. Comparative expression of renin-angiotensin pathway proteins in visceral vs. subcutaneous fat. *Front Physiol.* (2018) 9:1370. doi: 10.3389/fphys.2018.01370

28. Xiao L, Sakagami H, Miwa N. ACE2: the key molecule for understanding the pathophysiology of severe and critical conditions of COVID-19: demon or angel? *Viruses.* (2020) 12:491. doi: 10.3390/v12050491

29. Neeland IJ, Ross R, Després JP, Matsuzawa Y, Yamashita S, Shai I, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. *Lancet Diabetes Endocrinol.* (2019) 7:715–25. doi: 10.1016/S2213-8587(19)30084-1

30. Lorincz-Comí N, Zha X. Cardiometabolic risks of SARS-CoV-2 hospitalization using Mendelian randomization. *Sci Rep.* (2021) 11:7848. doi: 10.1038/s41598-021-86757-3

31. Zhang Y, Mao Q, Li Y, Cheng J, Xia Q, Chen G, et al. Cancer and COVID-19 susceptibility and severity: a two-sample mendelian randomization and bioinformatic analysis. *Front Cell Dev Biol.* (2021) 9:759257. doi: 10.3389/fcell.2021.759257

32. Aveyard P, Gao M, Lindson N, Hartmann-Boyce J, Watkinson P, Young D, et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. *Lancet Respir Med.* (2021) 9:909–23. doi: 10.1016/S2213-2600(21)00095-3

33. Vissers D, Hens W, Taeymans J, Baeyens JP, Poortmans J, Van Gaal L. The effect of exercise on visceral adipose tissue in overweight adults: a systematic review and meta-analysis. *PLoS ONE.* (2013) 8:e56415. doi: 10.1371/journal.pone.0056415

34. Verheggen RJ, Maessen MF, Green DJ, Hermus AR, Hopman MT, Thijsen DH, et al. Systematic review and meta-analysis on the effects of exercise training vs. hypocaloric diet: distinct effects on body weight and visceral adipose tissue. *Obes Rev.* (2016) 17:664–80. doi: 10.1111/obr.12486

35. Watanabe M, Balena A, Masi D, Tozzi R, Rui R, Caputi A, et al. Rapid weight loss, central obesity improvement and blood glucose reduction are associated with a stronger adaptive immune response following COVID-19 mRNA vaccine. *Vaccines.* (2022) 10:79. doi: 10.3390/vaccines10010079

36. Mary Schooling C, Zhao JY, Au Yeung SL, Kwok MK. Letter in response to ‘Bias in two-sample Mendelian randomization when using heritable covariable-adjusted summary associations’ ‘Interpreting Mendelian randomization studies pre-adjusted for the heritable covariable survival to recruitment’. *Int J Epidemiol.* (2021) 50:1744–5. doi: 10.1093/ije/dyab126